StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research report report published on Sunday. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

Shares of OPGN opened at $1.90 on Friday. OpGen has a 52 week low of $1.75 and a 52 week high of $38.40. The stock’s 50-day moving average price is $2.31 and its 200-day moving average price is $3.63.

OpGen (NASDAQ:OPGN) last posted its earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share (EPS) for the quarter. OpGen had a negative net margin of 1,140.36% and a negative return on equity of 1,827.76%. The firm had revenue of $0.03 million during the quarter.

Institutional Investors Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp bought a new stake in OpGen, Inc. (NASDAQ:OPGN) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen as of its most recent SEC filing. Institutional investors and hedge funds own 2.68% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.